Fred Hutch Cancer Center | Strategic Alliance Partners

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Michael J. Wagner, MD, talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward, and the potential for immunotherapy in this disease.

Petros Grivas, MD, PhD, discusses the phase 2 TROPHY U-01 trial in metastatic urothelial cancer.

Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.

Although brachytherapy is rarely utilized as a treatment for pediatric and adolescent/young adult patients in the United States, AYA patients with rhabdomyosarcoma treated with BT had favorable survival outcomes.

A subtle superstar, Nancy E. Davidson, MD, is as adept at conducting groundbreaking research as she is at treating patients and corralling investigators.

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.

Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

Evan Y. Yu, MD, provided insight into treatment sequencing for patients with metastatic urothelial carcinoma, considerations for treatment decisions, and emerging therapies in the paradigm. 

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.